- Home
- XBIO vs GNPX Comparison
XBIO vs GNPX Comparison
Compare XBIO & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- GNPX
- Stock Information
- Founded
- XBIO N/A
- GNPX 2009
- Country
- XBIO United States
- GNPX United States
- Employees
- XBIO N/A
- GNPX N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- GNPX Health Care
- Exchange
- XBIO Nasdaq
- GNPX Nasdaq
- Market Cap
- XBIO 5.8M
- GNPX 6.1M
- IPO Year
- XBIO N/A
- GNPX 2018
- Fundamental
- Price
- XBIO $2.53
- GNPX $0.34
- Analyst Decision
- XBIO Hold
- GNPX Strong Buy
- Analyst Count
- XBIO 1
- GNPX 1
- Target Price
- XBIO N/A
- GNPX $10.00
- AVG Volume (30 Days)
- XBIO 7.1K
- GNPX 9.6M
- Earning Date
- XBIO 05-08-2025
- GNPX 05-13-2025
- Dividend Yield
- XBIO N/A
- GNPX N/A
- EPS Growth
- XBIO N/A
- GNPX N/A
- EPS
- XBIO N/A
- GNPX N/A
- Revenue
- XBIO $2,500,284.00
- GNPX N/A
- Revenue This Year
- XBIO $14.23
- GNPX N/A
- Revenue Next Year
- XBIO N/A
- GNPX N/A
- P/E Ratio
- XBIO N/A
- GNPX N/A
- Revenue Growth
- XBIO N/A
- GNPX N/A
- 52 Week Low
- XBIO $2.26
- GNPX $0.22
- 52 Week High
- XBIO $5.20
- GNPX $4.09
- Technical
- Relative Strength Index (RSI)
- XBIO 25.28
- GNPX 46.59
- Support Level
- XBIO $2.26
- GNPX $0.22
- Resistance Level
- XBIO $3.43
- GNPX $0.44
- Average True Range (ATR)
- XBIO 0.21
- GNPX 0.07
- MACD
- XBIO -0.07
- GNPX 0.01
- Stochastic Oscillator
- XBIO 16.67
- GNPX 36.70
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.